DE102011088270A1 - (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot's disease Marie Toot - Google Patents

(11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot's disease Marie Toot Download PDF

Info

Publication number
DE102011088270A1
DE102011088270A1 DE102011088270A DE102011088270A DE102011088270A1 DE 102011088270 A1 DE102011088270 A1 DE 102011088270A1 DE 102011088270 A DE102011088270 A DE 102011088270A DE 102011088270 A DE102011088270 A DE 102011088270A DE 102011088270 A1 DE102011088270 A1 DE 102011088270A1
Authority
DE
Germany
Prior art keywords
charcot
marie
disease
estra
pentafluoroethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102011088270A
Other languages
German (de)
Inventor
wird später genannt werden Erfinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Priority to DE102011088270A priority Critical patent/DE102011088270A1/en
Priority to PCT/EP2012/074972 priority patent/WO2013087575A1/en
Priority to TW101147019A priority patent/TW201330853A/en
Publication of DE102011088270A1 publication Critical patent/DE102011088270A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

Die Erfindung betrifft die Behandlung von Morbus Charcot Marie Tooth mit dem Progesteronrezeptorantagonisten (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on und seinen pharmazeutisch verträglichen Salzen.The invention relates to the treatment of Charcot Marie Tooth's disease with the progesterone receptor antagonist (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one and its pharmaceutically acceptable salts.

Description

Die Erfindung betrifft die Behandlung von Morbus Charcot Marie Tooth mit dem Progesteronrezeptorantagonisten (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on und seinen pharmazeutisch verträglichen Salzen. The invention relates to the treatment of Charcot Marie Tooth's disease with the progesterone receptor antagonist (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one and its pharmaceutically acceptable salts.

(11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on, seine Herstellung und Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere von Uterusfibroiden (Myomen, uterine Leiomyome), der Endometriose, schweren Menstruationsblutungen, Meningiomen, hormonabhängigen Mammakarzinomen und von mit der Menopause assoziierten Beschwerden oder zur Fertilitätskontrolle und Notfallkontrazeption ist aus WO 2011009531. (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on hat die Formel:

Figure 00010001
(11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one, its preparation and use for the treatment and / or prophylaxis of diseases and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, in particular uterine fibroids (fibroids, uterine leiomyomas), endometriosis, severe menstrual bleeding, meningiomas, hormone-dependent breast cancers and menopausal complaints or for fertility control and emergency contraception WO 2011009531. (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one has the formula:
Figure 00010001

Dabei handelt es sich um einen selektiven Progesteronrezeptorantagonisten, also einen Wirkstoff, der die die Wirkung des Progesterons an seinem Rezeptor inhibiert. It is a selective progesterone receptor antagonist, ie an active substance that inhibits the action of progesterone on its receptor.

(11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on kann darüber hinaus zur Behandlung und/oder Prophylaxe von PR positiven Tumoren (der Brust, des Ovars, des Endoemtriums, der Zervix, der Prostata, von Leiomyosarcomen, Gliomen, Meningiomen oder Desmoid Tumoren) eingesetzt werden. Es ist weiterhin zur Behandlung von Neurofibromen und neuromuskulären Erkrankungen wie bspw. Morbus Charcot-Marie-Tooth geeignet. Außerdem sind in der Tiermedizin Anwendungen zur Geburtseinleitung, zur Behandlung von Pyometra, Hyperplasien der Brustdrüse insbesondere bei weiblichen Hunden und Katzen denkbar. Außerdem kommen alle Progesteronabhängigen Neoplasien auch in der Tierheilkunde in Betracht. In addition, (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one may be used for the treatment and / or prophylaxis of PR positive tumors (breast, ovary, endoemtrium, cervix, prostate, leiomyosarcoma, glioma, meningioma or desmoid tumors). It is also suitable for the treatment of neurofibromas and neuromuscular diseases such as, for example, Charcot-Marie-Tooth's disease. In addition, in the veterinary medicine applications for labor induction, for the treatment of pyometra, hyperplasia of the mammary gland in particular in female dogs and cats are conceivable. In addition, all progesterone-dependent neoplasms come into consideration in veterinary medicine.

Gegenstand der vorliegenden Anmeldung ist die Behandlung von Morbus Charcot-Marie-Tooth (vergl. hierzu: Patzkó et al: Update on Charcot-Marie-Tooth Disease, Curr Neurol Neurosci Rep (2011) 11:78–88 und Rareyson et al: Diagnosis, natural history, and management of Charcot-Marie-Tooth disease, Lancet Neurol 2009; 8: 654–67 ). The subject matter of the present application is the treatment of Charcot-Marie-Tooth's disease (cf. Patzkó et al: Update on Charcot-Marie-Tooth Disease, Curr Neurol Neurosci Rep (2011) 11: 78-88 and Rareyson et al: Diagnosis, natural history, and management of Charcot-Marie-Tooth disease, Lancet Neurol 2009; 8: 654-67 ).

Morbus Charcot-Marie-Tooth (CMT, auch hereditäre motorisch-sensible Neuropathie Typ I oder neurale Muskelatrophie genannt) gehört zu den neuromuskulären Erkrankungen. Sie ist eine der häufigsten neurogenetische Erkrankungen. Dabei werden entweder der Nervenzellfortsatz (Axon) oder die isolierende Myelinschicht geschädigt und dadurch die Weiterleitung von Nervenimpulsen in peripheren Nerven behindert, so dass die Befehle des Gehirns die Muskeln nicht richtig erreichen können. Aus der Denervierung resultiert der Abbau der betroffenen Muskulatur. CMT Typ 1 und 1A (CMT1/1A) sind die häufigsten Formen der genetisch heterogenen Gruppe der CMT Erkrankungen. In den meisten Fällen liegt bei der CMT1A eine Verdoppelung einer bestimmten Region des Chromosomes 17p12 vor, die das Gen PMP22 enthält. Die Schwann-Zellen, die die Axons umgeben, exprimieren PMP22 als wichtigen Baustein der Myellinhülle, die für die elektrische Isolation notwendig ist. Verschiedenste Studien haben gezeigt, dass der Expressionslevel von PMP22 den Typ und das Ausmaß der Neuropathie in dieser Erkrankung bestimmt. Neurone und Schwann-Zellen exprimieren zudem Progesteron. In kultivierten Schwann’schen Zellen wurde gezeigt, dass Progesteron die PMP22 Expression stimuliert.. Charcot-Marie-Tooth disease (CMT, also called hereditary motor-sensory neuropathy type I or neural muscular atrophy) is one of the neuromuscular diseases. It is one of the most common neurogenic diseases. This either damages the nerve cell process (axon) or the insulating myelin layer, thereby hindering the transmission of nerve impulses in peripheral nerves, so that the commands of the brain can not properly reach the muscles. The denervation results in the breakdown of the affected muscles. CMT type 1 and 1A (CMT1 / 1A) are the most common forms of the genetically heterogeneous group of CMT disorders. In most cases, CMT1A duplicates a specific region of chromosome 17p12, which contains the gene PMP22. The Schwann cells surrounding the axons express PMP22 as an important building block of the myelin sheath necessary for electrical isolation. Various studies have shown that the expression level of PMP22 determines the type and extent of neuropathy in this disease. Neurons and Schwann cells also express progesterone. In cultured Schwann cells, progesterone has been shown to stimulate PMP22 expression.

Alle Formen und Ausprägungen der CMT, bei denen Veränderungen von PMP22 auftreten, kommen als therapeutische Optionen in Betracht (u.a. CMT1, CMT1A, CMT4 auch autosomal rezessive CMT1 genannt). Zudem dient die Analyse auf Verdopplung des Genlocus von PMM22 (zur Patienten-Selektion). Die verringerte Expression von PMP22 während der Behandlung kann als Biomarker dienen. All forms and manifestations of CMT in which changes in PMP22 occur are considered therapeutic options (inter alia, CMT1, CMT1A, CMT4 also called autosomal recessive CMT1). In addition, the analysis serves to double the gene locus of PMM22 (for patient selection). The reduced expression of PMP22 during treatment may serve as a biomarker.

Patienten deren CMT-Erkrankung auf dieser Mutation beruht, profitieren besonders von einer Behandlung mit (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on. Patients whose CMT disease is based on this mutation benefit particularly from treatment with (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-diene 3-one.

Es ist bekannt, dass Progesteronrezeptorantagonisten im Tiermodell Morbus Charcot Marie Tooth positiv beeinflussen ( Sereda et a.: Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533–1537 (2003) ). Es kann nunmehr gezeigt werden, dass (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on im Tiermodell eine vergleichbare Wirkung zeigte, dabei aber die Nachteile von Onapriston vermied. It is known that progesterone receptor antagonists in the animal model positively influence Charcot's disease Marie Tooth ( Sereda et al .: Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533-1537 (2003) ). It can now be shown that (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one showed a comparable effect in the animal model while avoiding the disadvantages of Onapriston.

Zur Behandlung von Morbus Charcot-Marie-Tooth kann (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on mit weiteren Wirkstoffen, insbesondere mit Ascorbinsäure kombiniert werden. For the treatment of Charcot-Marie-Tooth's disease, (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one with other active substances , in particular be combined with ascorbic acid.

Die folgenden Beispiele dienen der Veranschaulichung der vorliegenden Erfindung ohne diese in irgend einer Weise zu begrenzen. The following examples serve to illustrate the present invention without limiting it in any way.

Beispiel 1: Behandlung von PMP22-transgenen CMT-Ratten mit (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on Example 1: Treatment of PMP22 transgenic CMT rats with (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one

Zufällig ausgewählte männliche PMP22-transgene CMT-Ratten (vergl. Sereda et al: A transgenic rat model of Charcot-Marie-Tooth disease, Neuron 16, 1049–1060 (1996) ) werden mit (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on (0,1 mg/kg, 1 mg/kg, 5 mg/kg oder 10 mg/kg) oder Progesteron (20 mg/kg) behandelt. Die Steroide werden dazu in Sesamöl auf suspendiert, an das steigende Körpergewicht angepasst und täglich subkutan zwischen P5 und P45 verabreicht. Die motorische Leistung der behandelten Tiere wird in einem standardisierten Stangentest überprüft. Ergänzend können weitere Untersuchungen (Progesteron-Radioimmunoassay; hüftnervhistologische und muskelpathologische Untersuchungen) durchgeführt werden. Eine genaue Beschreibung der Versuche findet sich bei Sereda et al (Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533–1537 (2003) . Randomly selected male PMP22 transgenic CMT rats (cf. Sereda et al: A transgenic rat model of Charcot-Marie-Tooth disease, Neuron 16, 1049-1060 (1996) ) are reacted with (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one (0.1 mg / kg, 1 mg / kg, 5 mg / kg or 10 mg / kg) or progesterone (20 mg / kg). The steroids are suspended in sesame oil, adjusted to the increasing body weight and administered daily subcutaneously between P5 and P45. The motor performance of the treated animals is tested in a standardized rod test. In addition, further examinations (progesterone radioimmunoassay, hip neovhistological and muscle pathological examinations) can be carried out. A detailed description of the experiments can be found at Sereda et al (Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533-1537 (2003) ,

ZITATE ENTHALTEN IN DER BESCHREIBUNG QUOTES INCLUDE IN THE DESCRIPTION

Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Zitierte PatentliteraturCited patent literature

  • WO 2011009531 [0002] WO 2011009531 [0002]

Zitierte Nicht-PatentliteraturCited non-patent literature

  • Patzkó et al: Update on Charcot-Marie-Tooth Disease, Curr Neurol Neurosci Rep (2011) 11:78–88 [0005] Patzkó et al: Update on Charcot-Marie-Tooth Disease, Curr Neurol Neurosci Rep (2011) 11: 78-88 [0005]
  • Rareyson et al: Diagnosis, natural history, and management of Charcot-Marie-Tooth disease, Lancet Neurol 2009; 8: 654–67 [0005] Rareyson et al: Diagnosis, natural history, and management of Charcot-Marie-Tooth disease, Lancet Neurol 2009; 8: 654-67 [0005]
  • Sereda et a.: Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533–1537 (2003) [0009] Sereda et al .: Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533-1537 (2003) [0009]
  • Sereda et al: A transgenic rat model of Charcot-Marie-Tooth disease, Neuron 16, 1049–1060 (1996) [0012] Sereda et al: A transgenic rat model of Charcot-Marie-Tooth disease, Neuron 16, 1049-1060 (1996) [0012]
  • Sereda et al (Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533–1537 (2003) [0012] Sereda et al (Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533-1537 (2003) [0012]

Claims (6)

(11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot-Marie-Tooth. (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot-Marie-Tooth's disease. (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot- Marie-Tooth nach Anspruch 1 in Kombination mit Ascorbinsäure. (11β, 17β) -17-hydroxy-11- [4- (methylsulphonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot-Marie-Tooth's disease according to claim 1 in Combination with ascorbic acid. Verwendung von (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot-Marie-Tooth. Use of (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot-Marie-Tooth's disease. Verwendung von (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Herstellung eines Arzneimittels zur Behandlung von Morbus Charcot-Marie-Tooth. Use of (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the manufacture of a medicament for the treatment of Charcot-Marie disease -Tooth. Arzneimittel enthaltend (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot-Marie-Tooth. Medicaments containing (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot-Marie-Tooth's disease. Arzneimittel nach Anspruch 5 enthaltend (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on und Ascorbinsäure. Medicament according to claim 5 containing (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one and ascorbic acid.
DE102011088270A 2011-12-12 2011-12-12 (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot's disease Marie Toot Withdrawn DE102011088270A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE102011088270A DE102011088270A1 (en) 2011-12-12 2011-12-12 (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot's disease Marie Toot
PCT/EP2012/074972 WO2013087575A1 (en) 2011-12-12 2012-12-10 (11ss,17ss)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoro- ethyl)estra-4,9-dien-3-one for the treatment of charcot marie tooth disease
TW101147019A TW201330853A (en) 2011-12-12 2012-12-12 (11 β ,17 β )-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for treating Charcot-Marie-Tooth disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011088270A DE102011088270A1 (en) 2011-12-12 2011-12-12 (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot's disease Marie Toot

Publications (1)

Publication Number Publication Date
DE102011088270A1 true DE102011088270A1 (en) 2013-06-13

Family

ID=47326166

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102011088270A Withdrawn DE102011088270A1 (en) 2011-12-12 2011-12-12 (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot's disease Marie Toot

Country Status (3)

Country Link
DE (1) DE102011088270A1 (en)
TW (1) TW201330853A (en)
WO (1) WO2013087575A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3214092A1 (en) * 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009531A2 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694610A1 (en) * 2003-12-19 2006-08-30 Degussa AG Dispersion of a metal-oxide powder containing binding agent and layer obtained therewith
US20080096950A1 (en) * 2006-10-19 2008-04-24 Karl Richard Gibson Compounds Useful In Therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009531A2 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Patzkó et al: Update on Charcot-Marie-Tooth Disease, Curr Neurol Neurosci Rep (2011) 11:78-88
Rareyson et al: Diagnosis, natural history, and management of Charcot-Marie-Tooth disease, Lancet Neurol 2009; 8: 654-67
Sereda et a.: Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533-1537 (2003)
Sereda et al (Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A), Nature Medicine 9, 1533-1537 (2003)
Sereda et al: A transgenic rat model of Charcot-Marie-Tooth disease, Neuron 16, 1049-1060 (1996)

Also Published As

Publication number Publication date
TW201330853A (en) 2013-08-01
WO2013087575A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
EP2552404A1 (en) Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis
WO1999012531A2 (en) Hormonal contraceptive
Linher-Melville et al. Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1: 1 combination
Lonsdale and et al. The anticonvulsant effects of progesterone and 5α‐dihydroprogesterone on amygdala‐kindled seizures in rats
CN1607954A (en) Pregnane steroids for use in the treatment of cns dysfunction
Fry et al. T-type Ca2+ channels in non-vascular smooth muscles
EP2131825A1 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
DE102011088270A1 (en) (11β, 17β) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one for the treatment of Charcot's disease Marie Toot
CN101076340B (en) GABA-steroid antagonists and their use for the treatment of cns disorders
Wolfe et al. Action of Male Sex Hormone With and Without Estrin in the Female Rat.
Weninger et al. Anästhesie in der Gynäkologie
Flagstad et al. Congenital myasthenic syndrome in the dog breed Gammel Dansk Hønsehund: clinical, electrophysiological, pharmacological and immunological comparison with acquired myasthenia gravis
DE212009000115U1 (en) Ecdysone derivatives and their use
Saltzman et al. Maintenance of bone mass despite estrogen depletion in female common marmoset monkeys (Callithrix jacchus)
Hwang et al. Myasthenic crisis after a renal transplant successfully treated with intravenous immunoglobulin
Grant et al. The effect on the external parathyroid glands of the exposure of rabbits to ultra-violet light
JP2005504776A (en) Use of pregnane-diones or diols as neuropathic analgesics
CN103142619B (en) Pharmaceutical composition for treating dermatitis and preparation method thereof
Khurshid et al. EFFECT OF BICALUTAMIDE; AN ANTIANDROGEN, ON TESTICULAR WEIGHT IN ADULT RATS: Effect of Bicalutamide
Sommers et al. Ulcerative colitis lesions in irradiated rats
Frye et al. Oxytocin and/or steroid hormone binding globulin infused into the ventral tegmental area modulates progestogen-mediated lordosis
US20230210870A1 (en) Methods of treating female health conditions related to sex hormones
Rizany et al. Serum Vitamin D Levels, Visual Analog Scale Dysmenorrhea Score, and Endometriosis ASRM Classification: a Relationship Study
MORGAN et al. Estrogen Treatment in Alzheimer’s Disease
Wells et al. THE CORTINOMIMETIC ACTIVITY OF VARIOUS STEROLS1

Legal Events

Date Code Title Description
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20140701